Vanguard Value ETF
How Tax Reform Affected Abbott’s 4Q17 Performance
In 4Q17, Abbott Laboratories (ABT) reported $828 million in net losses, which came in at $0.48 per share.
ZBH’s 4Q17 Earnings Results Meet Analysts’ Estimates
Zimmer Biomet Holdings announced its 4Q17 and 2017 results on January 30. The company’s sales exceeded analysts’ estimates, while its adjusted earnings per share managed to meet estimates.
A Look at Johnson & Johnson’s 2018 Guidance
Johnson & Johnson (JNJ) provided 2018 guidance during the company’s earnings results release on January 23, 2018.
Developments in J&J’s Medical Device Business Could Drive Growth
In October 2017, Johnson & Johnson (JNJ) exited its insulin pump business, which was experiencing a decline in sales due to the intense competition in the insulin pump market.
Which Gilead Sciences Portfolio Could Give a Long-Term Boost
NASH is a chronic disease related to steatosis wherein fat accumulates in the liver and can lead to inflammation, progressive fibrosis, and cirrhosis.
Johnson & Johnson’s Segment-Wise Performance in 4Q17
Johnson & Johnson’s (JNJ) Pharmaceuticals segment reported 17.6% growth in revenues to ~$9.7 billion during 4Q17, compared to ~$8.2 billion during 4Q16.
Xeljanz Sees Rapid Adoption in 2017
Xeljanz demand trends In 3Q17, Pfizer’s (PFE) Xeljanz reported revenue of ~$348 million, marking YoY (year-over-year) growth of ~48.1%. The drug saw sales of $935 million in the first nine months of 2017, a 44.1% YoY rise. In 3Q17, the drug’s new rheumatology prescriptions rose significantly. In September 2017, Xeljanz accounted for 9.8% of new prescriptions for RA (rheumatoid arthritis) in […]
First-Line NSCLC Continues to Be a Major Indication for Keytruda
In May 2017, Keytruda’s chemotherapy combination regimen was approved by the U.S. Food and Drug Administration (or FDA) in a first-line metastatic NSCLC indication.
How Eli Lilly’s Forteo and Jardiance Are Performing
In 3Q17, Eli Lilly’s (LLY) Forteo generated revenues of $441.7 million, ~13% growth on a year-over-year (or YoY) basis and a 1% decline on a quarter-over-quarter basis.
Can Smart Beta Go Wrong?
The smart beta approach aims to benefit from market inefficiencies to deliver higher risk-adjusted returns and improve diversification.
Inside Baxter’s Recent Developments in Peritoneal Dialysis Care
Baxter International’s (BAX) PD (peritoneal dialysis) solutions are among the key growth drivers of the company’s renal therapies business.
How Are Pfizer’s Vaccines and Biosimilars Positioned after 3Q17?
In 3Q17, Pfizer’s vaccines business generated revenues of $1.6 billion, which reflected ~1% growth on a year-over-year (or YoY) basis.
Abbott on the Street: Analyst Recommendations
Abbott registered strong 3Q17 results, surpassing estimates for both sales and earnings and reporting healthy growth across all of its business segments.
How JNJ’s Medical Devices Business Restructuring Efforts Are Panning Out
In 3Q17, Johnson & Johnson (JNJ) reported ~$19.7 billion in sales. The company’s Medical Devices business generated ~33.5% of the total sales.
Zimmer Biomet’s Knee Sales in 3Q17: What’s Ahead?
In the quarter ended September 30, 2017, Zimmer Biomet Holdings (ZBH) registered a YoY (year-over-year) fall of 1.5% on a constant currency basis, excluding the impact of the LDR acquisition.
Abbott-Alere Deal Wins Conditional US Antitrust Approval
The Federal Trade Commission recently announced the US antitrust approval for Abbott Laboratories’ (ABT) acquisition of Alere (ALR).
ZBH’s Persona Partial Knee Launch Expands Knee Implant Portfolio
On September 11, 2017, Zimmer Biomet Holdings (ZBH) announced the launch of its Persona Partial Knee System.
How Merck’s Vaccines Business Is Positioned after 2Q17
In 2Q17, Merck’s (MRK) Gardasil/Gardasil 9 generated revenues of ~$469 million, which reflected ~19% growth year-over-year and ~12% growth quarter-over-quarter.
JNJ on the Street: The Analyst View after the 2Q17 Results
Of the 22 brokerage firms covering JNJ, ten (~45%) have rated the stock a “buy,” while 12 (55%) have rated it as a “hold.” None has rated the stock a “sell.”
Bridion Could Drive Merck’s Acute Hospital Care Franchise in 2017
In 2016, Primaxin reported revenues of around $297 million compared to $313 million in 2015.
How Johnson & Johnson Is Bulking up in Orthopedics Devices
JNJ reported ~$17.8 billion in revenues in 1Q17, registering a YoY sales growth of around 1.6%. Its Medical Device segment reported ~3% growth.
Technological Advancements Drive Abbott’s New Product Approvals
On May 8, 2017, Abbott Laboratories (ABT) announced the CE Marking approval of its Confirm Rx ICM. ABT stock rose 0.09% that day.
Baxter’s Renal Business Continues to Be Key Growth Driver
In 1Q17, Baxter’s (BAX) renal segment reported revenues close to $896.0 million, which is an operational growth of around 2.0% YoY.
Jury Hasn’t Decided on ETFs’ Role in Stock Market Rise
Although ETF (VTV) ownership increased substantially during the last 20 years, it still isn’t high enough to meaningfully impact stock prices.
Merck: Keytruda Label Continues to Expand in 2017
Besides lung cancer and melanoma, Merck (MRK) is aggressively expanding Keytruda’s label across multiple cancer indications.
Quest Diagnostics’ Reference Testing, Hospital Outreach Segment
With services offered to about half of the total hospitals, Quest Diagnostics (DGX) has become a leading provider of reference testing services in the United States.
UnitedHealth Group Witnessed Robust Customer Growth in 1Q17
In 1Q17, UnitedHealth Group’s (UNH) UnitedHealthcare business witnessed a 2.5 million year-over-year increase in customers.
Merck Expected to Witness Rise in Its Net Profit Margin in 2017
For 2017, Merck & Co. (MRK) has projected its generally accepted accounting principles (or GAAP) earnings per share (or EPS) to fall in the range of $2.47–$2.62.
OptumRx Continues to Boost UnitedHealth’s Pharmacy Care Services
In its bid to control healthcare costs, UnitedHealth Group’s (UNH) OptumRx segment has been actively deploying data analytics across its Optum platform.
Inside the Latest Capability Advancement in Johnson & Johnson’s Orthopedics
On January 9, JNJ’s Medical Device division announced its Orthopedic Episode of Care Approach, a data-driven program that will accelerate value-based care.
Analyzing Zimmer Biomet Holdings’ Financial Guidance for 2016
Zimmer Biomet revised its 2016 guidance after reporting its 3Q16 earnings. Its guidance for fiscal 2016 is estimated to be $7.63 billion–$7.65 billion.
Baxter Advances Portfolio with Acquisition of Claris Injectables
Through the acquisition of Claris Injectables, Baxter International aims to accelerate its strategy to become a leader in the global injectables market.
Alere’s Response to Abbott Laboratories’s Lawsuit to Terminate the Merger
Alere (ALR) denied claims that any of the events that occurred during the last ten months would constitute any material change to the company’s value.
What’s Fueling the Bull Run? Richard Bernstein Explains
A bull run with legs In Richard Bernstein Advisors’ October Insights newsletter, after dismissing the belief that the Federal Reserve is to blame for stock price inflation (IWD) (VTV), Richard Bernstein moved on to explain the reason for the current bull run. Stating that “fundamentals have improved dramatically, and have been a major support to the […]
September 2016 Projections: US GDP Growth and Unemployment
FOMC (Federal Open Market Committee) participants have toned down their projections for US GDP growth in 2016 for the second successive quarter.
US Student Debt: A $5,000 Debt Needs More Attention Than $100,000
A small-ticket loan of $5,000 could be more harmful to the health of the US economy (SPY) (IWM) (QQQ) than a $100,000 loan.
Has the Brexit Vote Derailed US Monetary Policy?
After the policy meeting in June, Fed Chair Janet Yellen said that the Brexit vote could impact US monetary policy.
Bunge Has Declared a Quarterly Dividend of $0.38 per Share
Bunge (BG) has a market capitalization of $7.7 billion. BG rose by 0.56% to close at $50.0 per share as of March 1, 2016.